Ed. Note: This article was originally posted on June 15, 2021. It is being re-run here because we’re getting questions as this is touted as a “brand new buy alert” in recent ads, the ads themselves have not changed and this particular article has not been updated since publication. FYI: The stock teased, DNLI, is currently about 30% below where it traded on that day.
Alzheimer’s Disease is on everyone’s mind these days, thanks to Biogen’s (BIIB) controversial FDA approval for marketing Aduhelm as the first Alzheimer’s treatment in years, and arguably the first disease-modifying treatment at all… so both hope (for patients and families) and greed (for investors) are back in the picture.